H.C. Wainwright Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $30
Buy Rating for Olema Pharmaceuticals: Promising Preclinical Data and Strategic Pipeline Synergy
Olema Oncology Highlights Presentation Of Preclinical Data Demonstrating Anti-Tumor Activity For OP-3136
Why Intuitive Surgical Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Olema Pharmaceuticals Will Be Presenting Multiple Posters During The EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics (ENA 2024)
Express News | Olema Oncology Announces New Preclinical Combination Data to Be Presented at the 2024 Eortc-Nci-AACR Symposium on Molecular Targets and Cancer Therapeutics